Jump to content

Geographic atrophy

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 09:26, 30 August 2023 (Add: doi-access. | Use this bot. Report bugs. | Suggested by Headbomb | Linked from Wikipedia:WikiProject_Academic_Journals/Journals_cited_by_Wikipedia/Sandbox3 | #UCB_webform_linked 775/1975). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, choriocapillaris) which can lead to a loss of visual function over time.[1][2][3][4] It is estimated that GA affects over 5 million people worldwide and approximately 1 million patients in the US,[5][6] which is similar to the prevalence of neovascular (wet) AMD, the other advanced form of the disease.

The incidence of advanced AMD, both geographic atrophy and neovascular AMD, increases exponentially with age. The aim of most current clinical trials is to reduce the progression of GA lesion enlargement.[7]

Presentation

Geographic atrophy is a chronic disease, which leads to visual function loss. This often results in difficulties performing daily tasks such as reading, recognizing faces, and driving, and ultimately has severe consequences on independence.[8][9][10]

Initially, patients often have good visual acuity if the GA lesions are not involved in the central macular, or foveal, region of the retina.[7][11] As such, a standard vision test may underrepresent the visual deficit experienced by patients who report challenges reading, driving or seeing in low light conditions.[12] Reading speed is often initially unaffected due to foveal sparing, but worsens progressively as the area of atrophy enlarges.[13][14][15] As the disease progresses, vision-related quality-of-life declines markedly.[16]

While fluorescein angiography and optical coherence tomography are today well established for diagnosing and tracking progression in geographic atrophy more complex diagnostic assessments may be required in the context of clinical trials.[17] In February 2023, the FDA approved Pegcetacoplan for the treatment of people with geographic atrophy secondary to age-related macular degeneration.[18]

Pathogenesis

The pathogenesis of GA is not fully understood yet. It is likely multifactorial and triggered by intrinsic and extrinsic stressors of the poorly regenerative retinal pigment epithelium (RPE), particularly oxidative stress caused by the high metabolic demand of photoreceptors, photo-oxidation, and environmental stressors such as cigarette smoke. Variations in several genes, particularly in the complement system, increase the risk of developing GA. This is an active area of research but the current hypothesis is that with aging, damage caused by these stressors accumulates, which coupled with a genetic predisposition, results in the appearance of drusen and lipofuscin deposits (early and intermediate AMD). These and other products of oxidative stress can trigger inflammation via multiple pathways, particularly the complement cascade, ultimately leading to loss of photoreceptors, RPE, and choriocapillaris, culminating in atrophic lesions that grow over time.[19][20]

Risk factors for GA progression

A plethora of in vivo risk factors for GA progression have been published and validated.[21]

Recent studies indicate that geographic atrophy may be due to deficiencies in blood flow within the choriocapillaris.[22][23][24] These studies used swept-source optical coherence tomography angiography to examine the choriocapillaris. Using imaging algorithms, they then determined which regions of the choriocapillaris had deficient blood flow, thus creating a heat map of the blood supply to the retinal pigment epithelium. They went on to use fundus autofluorescence to image the retinal pigment epithelium over the course of a year, this allowed them to map out the direction and magnitude with the geographic atrophy spread. They then found that regions of the choriocapillaris which had less blood flow were more likely to degenerate and become geographic atrophy. Since the choriocapillaris is the main blood supply of the retinal pigment epithelium, it is leading some to believe that geographic atrophy is primarily an ischemic disease (disease due to decreased blood flow).

It was also shown that non-exudative neovascular membranes, which can recapitulate the choriocapillaris, are associated with a markedly slower GA progression.[25] This further supports the vascular insufficiency hypothesis.

Diagnosis

Diagnosis of geographic atrophy is made by an ophthalmologist in the clinic. Fundus autofluorescence and optical coherence tomography angiography are imaging modalities that can be used in the diagnosis. While fundus autofluorescence is the standard modality for viewing geographic atrophy, optical coherence tomography can offer unique benefits. Optical coherence tomography angiography can help the physician see if there is any subretinal fluid in the eye.[26] This is useful because it could indicate that the patient may be developing wet AMD. Since patients with geographic atrophy are at higher risk for developing advanced wet AMD (neovascular AMD), this could be especially useful in the monitoring of patients with geography atrophy. If signs of neovascular AMD found, the physician can initiate treatment of wet age-related macular degeneration.[27]

Quantification of GA progression

Traditionally, GA progression is quantified in terms of the area of retinal pigment epithelium atrophy.[28] Multiple imaging methods can be applied to quantify this area of retinal pigment epithelium atrophy including short-wavelength (blue) fundus autofluorescence imaging,[29] green fundus autofluorescence imaging,[30] and en face optical coherence tomography imaging.[31]

However, more recent data suggest that photoreceptor degeneration is not limited to the area of retinal pigment epithelium atrophy, but extends beyond this area. These more subtle changes can be quantified by volumetric analyses of optical coherence tomography data.[32][33]

Treatment

In February 2023, Apellis Pharmaceuticals received the first FDA approval of pegcetacoplan for the treatment of this condition.[34]

Avacincaptad pegol (Izervay) was approved in the United States in August 2023 for the treatment of geographic atrophy secondary to age-related macular degeneration.[35][36]

References

  1. ^ Lindblad, AS; Lloyd, PC; Clemons, TE; Gensler, GR; Ferris FL, 3rd; Klein, ML; Armstrong, JR; Age-Related Eye Disease Study Research, Group. (September 2009). "Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26" (PDF). Archives of Ophthalmology. 127 (9): 1168–74. doi:10.1001/archophthalmol.2009.198. PMC 6500457. PMID 19752426.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  2. ^ Sunness, JS (3 November 1999). "The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration". Molecular Vision. 5: 25. PMID 10562649.
  3. ^ Bonilha, Vera L (2008). "Age and disease-related structural changes in the retinal pigment epithelium". Clinical Ophthalmology. 2 (2): 413–424. doi:10.2147/opth.s2151. ISSN 1177-5467. PMC 2693982. PMID 19668732.
  4. ^ Lindner, Moritz; Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Holz, Frank G. (2018), "Atrophy, Geographic", Encyclopedia of Ophthalmology, Springer Berlin Heidelberg, pp. 207–209, doi:10.1007/978-3-540-69000-9_1125, ISBN 9783540682929
  5. ^ Wong, Wan Ling; Su, Xinyi; Li, Xiang; Cheung, Chui Ming G; Klein, Ronald; Cheng, Ching-Yu; Wong, Tien Yin (February 2014). "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis". The Lancet Global Health. 2 (2): e106–e116. doi:10.1016/S2214-109X(13)70145-1. PMID 25104651.
  6. ^ Rudnicka, Alicja R.; Kapetanakis, Venediktos V.; Jarrar, Zakariya; Wathern, Andrea K.; Wormald, Richard; Fletcher, Astrid E.; Cook, Derek G.; Owen, Christopher G. (July 2015). "Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis". American Journal of Ophthalmology. 160 (1): 85–93.e3. doi:10.1016/j.ajo.2015.04.003. PMID 25857680.
  7. ^ a b Sadda, SriniVas R.; Chakravarthy, Usha; Birch, David G.; Staurenghi, Giovanni; Henry, Erin C.; Brittain, Christopher (October 2016). "Clinical Endpoints for the Study of Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retina. 36 (10): 1806–1822. doi:10.1097/IAE.0000000000001283. PMC 5384792. PMID 27652913.
  8. ^ Brown, Jamie C.; Goldstein, Judith E.; Chan, Tiffany L.; Massof, Robert; Ramulu, Pradeep (August 2014). "Characterizing Functional Complaints in Patients Seeking Outpatient Low-Vision Services in the United States". Ophthalmology. 121 (8): 1655–1662.e1. doi:10.1016/j.ophtha.2014.02.030. PMC 6746569. PMID 24768243.
  9. ^ Tschosik, Elizabeth; Leidy, Nancy Kline; Kimel, Miriam; Dolan, Chantal; Souied, Eric; Varma, Rohit; Bressler, Neil M. (11 June 2015). "Quantifying functional reading independence in geographic atrophy: the FRI Index". Investigative Ophthalmology & Visual Science. 56 (7): 4789. ISSN 1552-5783.
  10. ^ DeCarlo, DK; Scilley, K; Wells, J; Owsley, C (March 2003). "Driving habits and health-related quality of life in patients with age-related maculopathy". Optometry and Vision Science. 80 (3): 207–13. doi:10.1097/00006324-200303000-00010. PMID 12637832. S2CID 11146594.
  11. ^ Lindner, Moritz; Böker, Alexander; Mauschitz, Matthias M.; Göbel, Arno P.; Fimmers, Rolf; Brinkmann, Christian K.; Schmitz-Valckenberg, Steffen; Schmid, Matthias; Holz, Frank G. (July 2015). "Directional Kinetics of Geographic Atrophy Progression in Age-Related Macular Degeneration with Foveal Sparing". Ophthalmology. 122 (7): 1356–1365. doi:10.1016/j.ophtha.2015.03.027. ISSN 0161-6420. PMID 25972258.
  12. ^ Sunness, JS; Applegate, CA; Haselwood, D; Rubin, GS (September 1996). "Fixation patterns and reading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease". Ophthalmology. 103 (9): 1458–66. doi:10.1016/S0161-6420(96)30483-1. PMC 2730505. PMID 8841306.
  13. ^ Sunness JS, Rubin GS, Zuckerbrod A, Applegate CA (October 2008). "Foveal-Sparing Scotomas in Advanced Dry Age-Related Macular Degeneration". J Vis Impair Blind. 102 (10): 600–610. doi:10.1177/0145482X0810201004. PMC 2836024. PMID 20224750.
  14. ^ Lindner M, Pfau M, Czauderna J, Goerdt L, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (March 2019). "Determinants of Reading Performance in Eyes with Foveal-Sparing Geographic Atrophy". Ophthalmol Retina. 3 (3): 201–210. doi:10.1016/j.oret.2018.11.005. PMID 31014695. S2CID 81733640.
  15. ^ Künzel SH, Lindner M, Sassen J, Möller PT, Goerdt L, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (September 2021). "Association of Reading Performance in Geographic Atrophy Secondary to Age-Related Macular Degeneration With Visual Function and Structural Biomarkers". JAMA Ophthalmol. 139 (11): 1191–1199. doi:10.1001/jamaophthalmol.2021.3826. PMC 8485212. PMID 34591067.
  16. ^ Künzel SH, Möller PT, Lindner M, Goerdt L, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (May 2020). "Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration". Invest Ophthalmol Vis Sci. 61 (5): 63. doi:10.1167/iovs.61.5.63. PMC 7405807. PMID 32462198.
  17. ^ Holz, Frank G.; Sadda, SriniVas R.; Staurenghi, Giovanni; Lindner, Moritz; Bird, Alan C.; Blodi, Barbara A.; Bottoni, Ferdinando; Chakravarthy, Usha; Chew, Emily Y. (April 2017). "Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings". Ophthalmology. 124 (4): 464–478. doi:10.1016/j.ophtha.2016.12.002. ISSN 1549-4713. PMID 28109563.
  18. ^ "FDA Approves Syfovre (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness" (Press release). Apellis Pharmaceuticals. 17 February 2023. Archived from the original on 17 February 2023. Retrieved 18 February 2023 – via GlobeNewswire.
  19. ^ Holz, Frank G.; Strauss, Erich C.; Schmitz-Valckenberg, Steffen; van Lookeren Campagne, Menno (May 2014). "Geographic atrophy: clinical features and potential therapeutic approaches". Ophthalmology. 121 (5): 1079–1091. doi:10.1016/j.ophtha.2013.11.023. PMID 24433969.
  20. ^ Saleh Abdelfattah, Nizar; Zhang, Hongyang; Boyer, David S.; Sadda, SriniVas R. (2016). "Progression of Macular Atrophy in Patients with Neovascular Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor Therapy". Retina. 36 (10): 1843–1850. doi:10.1097/iae.0000000000001059. PMID 27135213. S2CID 28757961.
  21. ^ Fleckenstein M, Mitchell P, Freund KB, Sadda S, Holz FG, Brittain C, Henry EC, Ferrara D (March 2018). "The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration". Ophthalmology. 125 (3): 369–390. doi:10.1016/j.ophtha.2017.08.038. PMID 29110945.
  22. ^ Thulliez, M (June 2019). "Correlations between Choriocapillaris Flow Deficits around Geographic Atrophy and Enlargement Rates Based on Swept-Source OCT Imaging". Ophthalmol Retina. 3 (6): 478–488. doi:10.1016/j.oret.2019.01.024. PMID 31174669. S2CID 86851083.
  23. ^ Nassisi, M (21 August 2018). "Choriocapillaris impairment around the atrophic lesions in patients with geographic atrophy: a swept-source optical coherence tomography angiography study". Br J Ophthalmol. 103 (7): 911–917. doi:10.1136/bjophthalmol-2018-312643. PMID 30131381.
  24. ^ Müller PL, Pfau M, Möller PT, Nadal J, Schmid M, Lindner M, de Sisternes L, Stöhr H, Weber BH, Neuhaus C, Herrmann P, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (March 2018). "Choroidal Flow Signal in Late-Onset Stargardt Disease and Age-Related Macular Degeneration: An OCT-Angiography Study". Invest Ophthalmol Vis Sci. 59 (4): AMD122–AMD131. doi:10.1167/iovs.18-23819. PMID 30140905. S2CID 52077435.
  25. ^ Pfau M, Möller PT, Künzel SH, von der Emde L, Lindner M, Thiele S, Dysli C, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (March 2020). "Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration". Ophthalmol Retina. 4 (3): 238–248. doi:10.1016/j.oret.2019.09.016. PMID 31753808. S2CID 208226972.
  26. ^ Garcia-Layana, Alfredo. "Optical Coherence Tomography in Age-related Macular Degeneration". AMD book. Retrieved 8 December 2019.
  27. ^ Malciolu Radu Alexandru (January–March 2016). "Wet age-related macular degeneration management and follow-up". Rom J Ophthalmol. 60 (1): 9–13. PMC 5712923. PMID 27220225.
  28. ^ Fleckenstein, M; Mitchell, P; Freund, KB; Sadda, S; Holz, FG; Brittain, C; Henry, EC; Ferrara, D (March 2018). "The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration". Ophthalmology. 125 (3): 369–390. doi:10.1016/j.ophtha.2017.08.038. PMID 29110945.
  29. ^ Schmitz-Valckenberg S, Brinkmann CK, Alten F, Herrmann P, Stratmann NK, Göbel AP, Fleckenstein M, Diller M, Jaffe GJ, Holz FG (September 2011). "Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration". Invest Ophthalmol Vis Sci. 52 (10): 7640–6. doi:10.1167/iovs.11-7457. PMID 21873669.
  30. ^ Pfau M, Goerdt L, Schmitz-Valckenberg S, Mauschitz MM, Mishra DK, Holz FG, Lindner M, Fleckenstein M (May 2017). "Green-Light Autofluorescence Versus Combined Blue-Light Autofluorescence and Near-Infrared Reflectance Imaging in Geographic Atrophy Secondary to Age-Related Macular Degeneration". Invest Ophthalmol Vis Sci. 58 (6): BIO121–BIO130. doi:10.1167/iovs.17-21764. PMID 28632841. S2CID 10855695.
  31. ^ Shi Y, Zhang Q, Zhou H, Wang L, Chu Z, Jiang X, Shen M, Thulliez M, Lyu C, Feuer W, de Sisternes L, Durbin MK, Gregori G, Wang RK, Rosenfeld PJ (April 2021). "Correlations Between Choriocapillaris and Choroidal Measurements and the Growth of Geographic Atrophy Using Swept Source OCT Imaging". Am J Ophthalmol. 224: 321–331. doi:10.1016/j.ajo.2020.12.015. PMC 8058170. PMID 33359715.
  32. ^ Pfau M, von der Emde L, de Sisternes L, Hallak JA, Leng T, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Rubin DL (October 2020). "Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration". JAMA Ophthalmol. 138 (10): 1026–1034. doi:10.1001/jamaophthalmol.2020.2914. PMC 7426886. PMID 32789526.
  33. ^ Reiter GS, Told R, Schranz M, Baumann L, Mylonas G, Sacu S, Pollreisz A, Schmidt-Erfurth U (June 2020). "Subretinal Drusenoid Deposits and Photoreceptor Loss Detecting Global and Local Progression of Geographic Atrophy by SD-OCT Imaging". Invest Ophthalmol Vis Sci. 61 (6): 11. doi:10.1167/iovs.61.6.11. PMC 7415285. PMID 32503052.
  34. ^ FDA Approves First Treatment for Geographic Atrophy
  35. ^ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 18 August 2023. Retrieved 25 August 2023.
  36. ^ "Iveric Bio Receives U.S. FDA Approval for Izervay (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy" (Press release). Astellas Pharma Inc. 4 August 2023. Retrieved 25 August 2023 – via PR Newswire.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Geographic_atrophy&oldid=1172945007"